查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919253

抛弃式避光输液器市场按产品类型、材料、应用和通路－2026-2032年全球预测

Disposable Lightproof Infusion Set Market by Product Type, Material, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年抛弃式遮光输液器市值为 2.3245 亿美元，预计到 2026 年将成长至 2.5047 亿美元，到 2032 年将达到 3.8827 亿美元，复合年增长率为 7.60%。

关键市场统计数据
基准年 2025 2.3245亿美元
预计年份：2026年 2.5047亿美元
预测年份 2032 3.8827亿美元
复合年增长率 (%) 7.60%

针对抛弃式避光输液装置的临床应用和工程原理的全面指导，将有助于确定采购重点和设备选择。

抛弃式避光输液器是一种专用耗材，旨在保护光敏性治疗製剂在配製、给药和运输过程中免受损​​害。在临床实务中，对于某些抗癌药物、生物製药和复杂的肠外製剂而言，这些输液器的重要性日益凸显，因为光降解会影响药物的疗效、稳定性或病人安全。随着治疗方法的不断发展和门诊服务的扩展，诸如避光性、材料相容性、抗阻塞性和易用性等设备性能指标对临床医生、药剂师和采购团队而言变得越来越重要。

融合的临床工作流程、聚合物创新和永续性期望如何重新定义一次性输液装置的设计重点和采购标准

抛弃式避光输液器的市场格局正经历快速变化，这主要受到临床、技术和供应链因素的共同影响。在临床方面，复杂疗法的门诊和居家给药模式的转变，推动了对操作简单、能够在医院环境之外保持药物完整性的输液器的需求。在技​​术方面，聚合物科学和多层复合薄膜的进步，使得轻盈、柔软性、高性能的避光屏障成为可能，并可与多种输液方式无缝整合。

近期关税变化对抛弃式遮光输液器製造商和采购商的供应链设计、筹资策略和供应商韧性的影响

包括关税调整和2025年前的贸易政策更新在内的政策趋势，正对医疗设备供应链中的零件采购、製造地和成本结构产生显着影响。与原材料和成品关税相关的成本上涨，促使製造商重新评估供应商的地理分布，探索替代原材料，并加快二级供应商的资格认证。在许多情况下，这推动了策略性回流和区域化倡议，以降低跨境关税波动带来的风险，并缩短聚合物树脂、箔层压板和连接器组件等关键零件的前置作业时间。

透过对临床应用、最终用户、通路、产品类型和材料选择进行详细的细分映射，以推动差异化产品策略和市场推广。

详细的細項分析揭示了临床需求、产品结构和通路的交汇点，这些交汇点共同塑造了价值提案和市场接受模式。应用领域涵盖化疗输注、胰岛素输注、疼痛管理和肠外营养。化疗输注的应用案例根据联合治疗方案、单株抗体药物和青霉素製剂的不同而有所差异，每种方案都需要客製化的光阻隔和化学相容性。胰岛素输注的应用案例包括长效胰岛素输注装置、贴片式胰岛素输注装置及标准胰岛素输注装置。在长效胰岛素输注装置中，贴片式和帮浦式两种配置进一步细分，贴片式胰岛素又分为一次性贴片和可重复使用贴片。标准胰岛素输注装置根据导管规格进行区分，常见的规格有 22 号、24 号和 26 号。疼痛管理应用需要硬膜外镇痛和患者自控镇痛 (PCA) 输注装置的特定配方，而肠外营养则区分部分肠外营养和全肠外营养方法，从而对管路长度、过滤器集成和与多层光密屏障的兼容性有不同的要求。

区域趋势和监管环境对重点区域的产品设计选择、采购行为和在地化商业化策略产生影响

在关键地区，地理因素持续影响产品设计重点、监管方式和采购行为。在美洲，需求模式反映出对门诊服务和价值导向型采购的高度重视，采购者寻求的是便于居家使用并最大限度减少后续医疗资源消耗的设备。在欧洲、中东和非洲地区（EMEA），集中采购、公立医院竞标以及各地区标准的差异，造就了监管环境的异质性，促使企业需要製定广泛的监管策略和灵活的製造地，以满足不同的合规要求。在亚太地区，新兴市场快速的都市区化进程和对成本敏感的采购行为，迫使製造商提供分级产品系列，在高端功能和价格优势之间取得平衡，并发展本地生产伙伴关係关係。

输液设备供应领域现有企业、灵活的利基市场参与企业和重要合作伙伴之间的差异化，是由竞争动态和创新路径塑造的。

抛弃式遮光输液器的竞争格局呈现出多元化的特点，既有专注于设备创新的专业厂商，也有医疗耗材集团，以及一些新兴的、专注于材料科学和人体工学的利基企业。主要企业透过专有的遮光基材、整合的安全机制以及与门诊和居家医疗中使用的泵浦系统的更高相容性来实现差异化竞争。材料供应商和设备製造商之间的策略联盟正在创造机会，加速新产品上市，并透过合作研究检验临床优势。

为确保供应韧性、加速目标产品创新和优化通路合作，製造商和买家可采取实际的策略行动。

产业领导者应采取协作策略，以加强供应链安全，加速定向创新，并提供能够适应不断变化的医疗保健环境的产品。首先，透过与多家合格供应商合作以及对替代材料进行认证，实现采购多元化，可以降低受贸易政策波动和原材料成本波动的影响。在地化最终组装还能缩短前置作业时间，并提高对当地监管要求的应对力。其次，优先投资于多层光学屏障技术、可再生基材和连接器标准化等方面的研发，将有助于满足药物保护、环境合规性和易用性等临床需求，从而促进产品在门诊和居家医疗环境中的应用。

采用稳健的混合方法研究途径，结合临床医师访谈、医疗设备审核、监管分析和供应链评估，以确保获得可操作的洞见。

本执行摘要的分析基于混合调查方法，该方法结合了对关键相关人员的访谈、有针对性的设备和材料审核，以及涵盖监管申报文件、临床指南和采购文献的系统性二手研究。主要研究包括对临床医生、采购负责人、临床药师、材料科学家和供应链经理进行结构化访谈，以了解实际临床需求、失效模式和推广应用障碍。一项补充性的医疗设备审核评估了材料结构、光衰减特性、连接器相容性和包装设计，检验与最终用户相关的性能权衡。

整合技术进步、临床需求和供应连续性考量，以揭示决定产品在临床实践中相关性和应用的关键因素。

抛弃式防光输液器的发展受到以下因素的影响：药物保护的临床需求、聚合物和层压技术的成熟，以及以门诊和居家给药为重点的医疗服务模式的转变。这些因素共同凸显了产品策略的必要性，该策略需兼顾技术性能、法规遵循性和通路的适应性。投资于检验的防光材料、以用户为中心的设计以及强大的供应商网络的製造商，将能够更好地满足化疗、胰岛素输注、疼痛管理和经肠营养等各种应用场景在医疗环境中的复杂需求。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章抛弃式光防护输液器市场（依产品类型划分）

  • 导管输液装置
    • 钢导管
    • 特氟龙导管
  • 针头输液器
    • 皮下注射针
    • 安全针
  • 翼状输液器
    • 22号口径
    • 24号口径
    • 26号口径

第九章 按材料分類的抛弃式避光输液器市场

  • 聚乙烯
    • HDPE
    • LDPE
  • PVC
    • 硬质聚氯乙烯
    • 软聚氯乙烯

第十章 按应用分類的抛弃式光屏蔽输液器市场

  • 化疗输液
    • 联合治疗
    • 基于单株抗体的
    • PCN 基
  • 胰岛素注射
    • 长效胰岛素套装
      • 补丁类型
      • 泵浦相容型
    • 胰岛素贴片套装
      • 免洗片
      • 可重复使用的补丁
    • 标准胰岛素套装
      • 22号口径
      • 24号口径
      • 26号口径
  • 疼痛管理
    • 硬脊膜外输注装置
    • PCA输液装置
  • 肠外营养
    • 部分肠外营养
    • 全静脉营养

第十一章抛弃式光防护输液器市场（依分销管道划分）

  • 医院药房
    • 住院药房
    • 门诊药房
  • 网路药房
    • 直接面向患者的销售
    • 电子商务平台
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章抛弃式光防护输液器市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章抛弃式光保护输液器市场（按类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国抛弃式避光输液器市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国抛弃式光屏蔽输液器市场

第十六章：中国抛弃式光屏蔽输液器市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Angiplast Pvt. Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Fresenius Kabi AG
  • ICU Medical, Inc.
  • JCM MED
  • Medtronic plc
  • Nipro Corporation
  • Smiths Group plc
  • Terumo Corporation
  • Vygon SA
Product Code: MRR-F14BA1B34169

The Disposable Lightproof Infusion Set Market was valued at USD 232.45 million in 2025 and is projected to grow to USD 250.47 million in 2026, with a CAGR of 7.60%, reaching USD 388.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 232.45 million
Estimated Year [2026] USD 250.47 million
Forecast Year [2032] USD 388.27 million
CAGR (%) 7.60%

Comprehensive orientation to the clinical role and engineering fundamentals of disposable lightproof infusion sets shaping procurement priorities and device selection

Disposable lightproof infusion sets are specialized consumables engineered to protect light-sensitive therapeutic formulations during preparation, administration, and transport. In clinical practice these sets are increasingly relevant where photodegradation can compromise potency, stability, or patient safety, including certain oncologic agents, biologic therapies, and complex parenteral preparations. As therapy regimens evolve and outpatient care expands, device performance characteristics such as light attenuation, material compatibility, occlusion resistance, and ease of use have taken on greater significance among clinicians, pharmacists, and procurement teams.

Moreover, technological refinements and changing care pathways have elevated expectations for single-use devices to deliver predictable handling, regulatory compliance, and cost-effective disposability. Consequently, a nuanced understanding of device construction, clinical utility across care settings, and regulatory considerations is essential for stakeholders aiming to optimize therapy outcomes while managing supply continuity and total cost of care.

How converging clinical workflows, polymer innovation, and sustainability expectations are redefining design priorities and procurement criteria in disposable infusion devices

The landscape for disposable lightproof infusion sets is undergoing rapid transformation driven by intersecting clinical, technological, and supply chain forces. Clinically, the shift toward ambulatory and home administration of complex therapies requires devices that are both user-friendly and capable of preserving drug integrity outside controlled hospital environments. Technologically, advances in polymer science and multi-layer lamination films are enabling lighter, more flexible, and higher-performance light barriers that integrate seamlessly with a variety of infusion modalities.

At the same time, safety and environmental considerations are prompting a reappraisal of materials and packaging, incentivizing manufacturers to innovate with recyclable substrates and reduced-volume packaging. These shifts are also influencing payer and provider purchasing criteria, where lifecycle cost, infection control, and cold-chain independence are now evaluated in tandem. Consequently, industry players that align R&D with clinical workflows and sustainability goals will be better positioned to respond to evolving demand.

Implications of recent tariff shifts on supply chain design, sourcing strategies, and supplier resilience for disposable lightproof infusion set manufacturers and purchasers

Policy dynamics, including tariff adjustments and trade policy updates through 2025, have exerted measurable pressure on component sourcing, manufacturing footprints, and cost structures across the medical device supply chain. Tariff-related cost escalation on raw materials and finished goods has encouraged manufacturers to reassess supplier geographies, seek alternative feedstocks, and accelerate qualification of secondary suppliers. In many cases, this has catalyzed strategic reshoring or regionalization efforts to reduce exposure to cross-border tariff volatility and to shorten lead times for critical components such as polymer resins, foil laminates, and connector assemblies.

Beyond immediate cost implications, tariff shifts have also influenced commercial strategies: providers are increasingly scrutinizing total landed cost and supplier resilience, while manufacturers are renegotiating distribution agreements and exploring localized value-added assembly to preserve margin and service levels. In this context, firms that proactively diversify sourcing and integrate tariff risk assessment into procurement planning are finding clearer pathways to maintain competitive pricing and uninterrupted supply to clinical customers.

Detailed segmentation mapping across clinical applications, end users, distribution pathways, product types, and material choices that drive differentiated product strategies and adoption

A granular segmentation analysis reveals where clinical need, product architecture, and distribution converge to shape value propositions and adoption patterns. By application, the landscape spans chemotherapy infusion, insulin infusion, pain management, and parenteral nutrition. Chemotherapy infusion use cases can be differentiated across combination therapy regimens, monoclonal antibody-based agents, and penicillin-based preparations, each demanding tailored light protection and chemical compatibility. Insulin infusion scenarios include extended wear insulin sets, patch insulin sets, and standard insulin sets; within extended wear solutions there is further divergence between patch type and pump compatible type configurations, while patch insulin options can be subdivided into disposable patch and reusable patch models. Standard insulin sets vary by cannula gauge commonly available as 22 gauge, 24 gauge, and 26 gauge. Pain management applications require specific formulations for epidural infusion sets and patient-controlled analgesia infusion sets, and parenteral nutrition distinguishes between partial parenteral and total parenteral approaches that pose distinct requirements for tubing length, filter integration, and compatibility with multilayer light barriers.

End user segmentation highlights differences across ambulatory surgical centre, clinic, homecare, and hospital settings. Ambulatory surgical centre demand bifurcates into day surgery and outpatient clinic contexts, while clinic adoption varies between general clinic and specialist clinic environments. Homecare utilization is shaped by whether administration is RN administered or self administered, and hospital procurement reflects separate needs for private hospital and public hospital systems. Distribution channels further delineate how products reach end users: hospital pharmacies operate inpatient and outpatient pharmacy channels, online pharmacies may deploy direct to patient or e-commerce platform models, and retail pharmacies are differentiated between chain pharmacy and independent pharmacy outlets. Product type distinctions include catheter infusion set, needle infusion set, and winged infusion set; catheter options are available in steel catheter and Teflon catheter variants, needle infusion offerings include hypodermic needle and safety needle innovations, and winged infusion sets are commonly specified across 22 gauge, 24 gauge, and 26 gauge sizes. Material choices influence both performance and regulatory compliance, with polyethylene versus PVC options; polyethylene alternatives are further characterized as HDPE and LDPE grades, while PVC selections may be rigid PVC or soft PVC depending on flexibility and chemical resistance requirements.

Taken together, these intersecting segment dimensions underline that successful product strategies require precise alignment of device type, material science, and channel strategy with the clinical workflows and staffing models of the target end users. Consequently, segmentation insights should directly inform product roadmaps, supplier partnerships, and targeted commercial messaging.

Regional dynamics and regulatory landscapes that influence product design choices, procurement behavior, and localized commercialization strategies across major geographies

Geographic dynamics continue to shape product design priorities, regulatory approaches, and procurement behavior across major regions. In the Americas, demand patterns reflect a strong emphasis on outpatient care delivery and value-based procurement, with buyers seeking devices that facilitate home administration and minimize downstream healthcare utilization. Europe, Middle East & Africa present a heterogeneous regulatory landscape in which centralized procurement, public hospital tendering, and varying regional standards drive the need for broad regulatory strategy and flexible manufacturing footprints to meet diverse compliance expectations. Asia-Pacific shows a mix of rapid adoption in urban centers and cost-sensitive purchasing in emerging markets, prompting manufacturers to offer tiered product portfolios that balance premium features with affordability and local production partnerships.

These regional differences have important implications for go-to-market plans: supply continuity, regulatory dossiers, and localized clinical evidence are prioritized differently in each geography, and manufacturers that adapt product specifications and commercial models to local reimbursement frameworks and distribution norms achieve stronger in-market penetration. Furthermore, regional sustainability considerations and waste management practices are increasingly influencing material selection and end-of-life strategies across jurisdictions.

Competitive dynamics and innovation pathways shaping differentiation among established manufacturers, agile niche entrants, and materials partners in infusion device supply

The competitive environment for disposable lightproof infusion sets is characterized by a mix of specialized device innovators, medical consumables conglomerates, and emerging niche players focusing on material science and user ergonomics. Leading organizations are differentiating through proprietary light-blocking substrates, integrated safety mechanisms, and enhanced compatibility with pump systems used in ambulatory and homecare settings. Strategic partnerships between materials suppliers and device manufacturers are creating opportunities to accelerate new product introductions and to validate downstream clinical benefits through collaborative studies.

At the same time, smaller, agile entrants are leveraging targeted innovations-such as ultrathin lamination films, anti-kink tubing geometries, and simplified connector systems-to capture specific clinical niches and to compel incumbents to respond. Competitive positioning increasingly depends on the ability to demonstrate robust regulatory compliance, supply chain resilience, and clear value propositions for clinicians and procurement officers. Consequently, merger, acquisition, and licensing activity focused on polymer technology, safety features, and distribution reach will remain important levers for companies seeking scale and differentiated product portfolios.

Practical strategic actions for manufacturers and purchasers that secure supply resilience, accelerate targeted product innovation, and optimize channel alignment

Industry leaders should pursue a coordinated strategy that strengthens supply security, accelerates targeted innovation, and aligns product offerings with evolving care settings. First, diversifying procurement across multiple qualified suppliers and qualifying alternative materials reduces exposure to trade policy fluctuations and input cost variability, while regionalizing final assembly can shorten lead times and enhance responsiveness to local regulatory requirements. Second, prioritizing R&D investments in multi-layer light barrier technologies, recyclable substrates, and connector standardization will address clinical demands for drug protection, environmental compliance, and ease of use, thereby improving adoption across ambulatory and homecare scenarios.

Third, companies should expand clinical evidence generation through pragmatic trials and real-world evidence programs that quantify benefits in workflow efficiency, drug stability, and safety. Fourth, commercial strategies should emphasize channel optimization by strengthening partnerships with hospital pharmacies, enabling direct to patient e-commerce models where appropriate, and designing packaging configurations for retail and outpatient pharmacy distribution. Finally, embedding tariff and trade risk assessment into strategic planning and contractual terms will help preserve margins and maintain supply continuity during policy shifts.

Robust mixed-methods research approach combining clinician interviews, device audits, regulatory analysis, and supply chain evaluation to ensure actionable insights

The analysis underpinning this executive summary draws on a blended methodology combining primary stakeholder interviews, targeted device and materials audits, and systematic secondary research across regulatory filings, clinical guidance, and procurement literature. Primary research included structured interviews with clinicians, procurement officers, clinical pharmacists, materials scientists, and supply chain leaders to capture real-world needs, failure modes, and adoption constraints across care settings. Complementary device audits assessed material construction, light attenuation characteristics, connector compatibility, and packaging design to evaluate performance tradeoffs relevant to end users.

Secondary sources supplemented these insights by clarifying regulatory pathways, safety standards, and industry white papers that inform device design and labeling. Cross-validation techniques were used to reconcile qualitative findings with device specifications and reported clinical practices, and sensitivity checks ensured that thematic conclusions reflect consensus perspectives rather than isolated viewpoints. Where appropriate, supplier footprint analyses and tariff impact studies were incorporated to illuminate supply chain vulnerabilities and strategic responses.

Synthesis of technical evolution, clinical imperatives, and supply continuity considerations that will determine product relevance and adoption across care settings

The evolution of disposable lightproof infusion sets is being shaped by clinical demands for drug protection, the maturation of polymer and lamination technologies, and shifting care delivery models that emphasize outpatient and home administration. Taken together, these forces underscore the need for product strategies that balance technical performance, regulatory compliance, and channel adaptability. Manufacturers that invest in validated light-blocking materials, user-centric designs, and resilient supplier networks will be better able to meet the nuanced requirements of chemotherapy, insulin delivery, pain management, and parenteral nutrition applications across diverse care settings.

For healthcare providers and procurement organizations, evaluating device offerings requires a holistic lens that considers material compatibility, connector standards, and the operational realities of end users. Ultimately, success in this domain will depend on aligning innovation with pragmatic clinical workflows, transparent evidence generation, and strategic supply chain management to ensure that therapies remain safe, stable, and accessible to patients wherever they are administered.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Disposable Lightproof Infusion Set Market, by Product Type

  • 8.1. Catheter Infusion Set
    • 8.1.1. Steel Catheter
    • 8.1.2. Teflon Catheter
  • 8.2. Needle Infusion Set
    • 8.2.1. Hypodermic Needle
    • 8.2.2. Safety Needle
  • 8.3. Winged Infusion Set
    • 8.3.1. 22 Gauge
    • 8.3.2. 24 Gauge
    • 8.3.3. 26 Gauge

9. Disposable Lightproof Infusion Set Market, by Material

  • 9.1. Polyethylene
    • 9.1.1. Hdpe
    • 9.1.2. Ldpe
  • 9.2. Pvc
    • 9.2.1. Rigid PVC
    • 9.2.2. Soft PVC

10. Disposable Lightproof Infusion Set Market, by Application

  • 10.1. Chemotherapy Infusion
    • 10.1.1. Combination Therapy
    • 10.1.2. Monoclonal Antibody Based
    • 10.1.3. Pcn Based
  • 10.2. Insulin Infusion
    • 10.2.1. Extended Wear Insulin Set
      • 10.2.1.1. Patch Type
      • 10.2.1.2. Pump Compatible Type
    • 10.2.2. Patch Insulin Set
      • 10.2.2.1. Disposable Patch
      • 10.2.2.2. Reusable Patch
    • 10.2.3. Standard Insulin Set
      • 10.2.3.1. 22 Gauge
      • 10.2.3.2. 24 Gauge
      • 10.2.3.3. 26 Gauge
  • 10.3. Pain Management
    • 10.3.1. Epidural Infusion Set
    • 10.3.2. Pca Infusion Set
  • 10.4. Parenteral Nutrition
    • 10.4.1. Partial Parenteral
    • 10.4.2. Total Parenteral

11. Disposable Lightproof Infusion Set Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Inpatient Pharmacy
    • 11.1.2. Outpatient Pharmacy
  • 11.2. Online Pharmacies
    • 11.2.1. Direct To Patient
    • 11.2.2. E-Commerce Platform
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Disposable Lightproof Infusion Set Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Disposable Lightproof Infusion Set Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Disposable Lightproof Infusion Set Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Disposable Lightproof Infusion Set Market

16. China Disposable Lightproof Infusion Set Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Angiplast Pvt. Ltd.
  • 17.6. B. Braun Melsungen AG
  • 17.7. Baxter International Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Fresenius Kabi AG
  • 17.10. ICU Medical, Inc.
  • 17.11. JCM MED
  • 17.12. Medtronic plc
  • 17.13. Nipro Corporation
  • 17.14. Smiths Group plc
  • 17.15. Terumo Corporation
  • 17.16. Vygon SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STEEL CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STEEL CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STEEL CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TEFLON CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TEFLON CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TEFLON CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HYPODERMIC NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HYPODERMIC NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HYPODERMIC NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SAFETY NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SAFETY NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SAFETY NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HDPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HDPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HDPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY LDPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY LDPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY LDPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RIGID PVC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RIGID PVC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RIGID PVC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SOFT PVC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SOFT PVC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SOFT PVC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MONOCLONAL ANTIBODY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MONOCLONAL ANTIBODY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MONOCLONAL ANTIBODY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCN BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCN BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCN BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PUMP COMPATIBLE TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PUMP COMPATIBLE TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PUMP COMPATIBLE TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISPOSABLE PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISPOSABLE PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISPOSABLE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY REUSABLE PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY REUSABLE PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY REUSABLE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 22 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 24 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY 26 GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EPIDURAL INFUSION SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EPIDURAL INFUSION SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EPIDURAL INFUSION SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCA INFUSION SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCA INFUSION SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PCA INFUSION SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARTIAL PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARTIAL PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARTIAL PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TOTAL PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TOTAL PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY TOTAL PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY E-COMMERCE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY E-COMMERCE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY E-COMMERCE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CATHETER INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY NEEDLE INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY WINGED INFUSION SET, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY POLYETHYLENE, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PVC, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY CHEMOTHERAPY INFUSION, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY INSULIN INFUSION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY EXTENDED WEAR INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PATCH INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY STANDARD INSULIN SET, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST DISPOSABLE LIGHTPROOF INFUSION SET MA